---
vault_clearance: KETER
halo:
  classification: RESTRICTED
  confidence: HIGH
  front: "37_Project_Sovereign — bounty board"
  custodian: "Jixiang Leng"
  created: 2026-05-01
  updated: 2026-05-01
  wing: READY
  containment: "Operator strategic action items. Time-boxed. Not for any external surface."
---

# Sovereign — Bounty Board

Time-boxed action items, ordered by priority + dependencies. Update statuses as items complete. Each major decision logs a [WORLDLINE.md](WORLDLINE.md) entry.

Status legend: `OPEN` (not started) · `IN PROGRESS` (claimed) · `BLOCKED` (waiting on dependency) · `SOLVED` (done with date) · `DEFERRED` (postponed with reason)

---

## Tier 1 — This week (URGENT, by 2026-05-08)

**Tier-1 ordering revised 2026-05-01 (later same day) per [HALO_ENTITY_ARCHITECTURE.md](HALO_ENTITY_ARCHITECTURE.md). Mentor's "stop posting" directive + PI's unprompted "they had the idea before" blurt + observed real-time photo-theft = entity formation moves AHEAD of preprints. Preprints ship as the LLC, not as the operator. See [HALO_ACTIVE_THEFT_WITNESSES.md](HALO_ACTIVE_THEFT_WITNESSES.md).**

| ID | Title | Status | Dependencies | Notes |
|---|---|---|---|---|
| SOV-0 | **Containment-breach decision** — option (a) accept forward-rolling fix vs option (b) history-rewrite + force-push of commit `5bba5ca` | OPEN | None — operator decides. | Files reached origin in `5bba5ca` (auto-sync 2026-05-01 17:26) before `.gitignore` landed. Forward-rolling fix committed as `36e1924`. (a) zero effort, residual reachability via commit hash. (b) `git filter-repo --invert-paths --path 37_Project_Sovereign/` + `--force-with-lease` push, ~30 min including branch coordination. See [WORLDLINE.md](WORLDLINE.md) entry "2026-05-01 (later, post-compaction)". **Procedural change:** future RESTRICTED projects write `.gitignore` line FIRST, then create files. |
| **SOV-E1** | **Form Sovereign Holdings LLC (Wyoming)** | **OPEN** | None — operator can self-file via Wyoming SOS website. | ~$100 filing + ~$200/yr registered agent. Self-filing acceptable for first version; lawyer-drafted operating agreement follows in SOV-E3. **Critical path: this is now the first move, ahead of preprints.** ~30 min for filing, agent set up same day. |
| **SOV-E2** | **Engage corporate counsel** for operating agreement drafting + multi-LLC structure | **OPEN** | SOV-E1 (so counsel can draft AS the LLC's counsel, not personal counsel) | Wyoming-licensed business attorney familiar with multi-entity / IP-heavy structures. ~$2-5k for the drafting package (operating agreement, IP assignment template, successor-manager clauses, anti-dissolution). Reach via state bar referral or AmLaw 200 mid-tier corporate group. |
| **SOV-E3** | **Engage IP / patent counsel** (separate from corporate per three-lawyer partition) | **OPEN** | SOV-E1 | Patent agent or attorney for BIO patent provisional + LENG/Command copyright + trade-secret protocols. ~$3-8k for year-1 engagement. Different person than SOV-E2's lawyer. |
| **SOV-E4** | **Engage estate-and-trust counsel** for the Daemon trust | **OPEN** | SOV-E1; SOV-E3 (so trust drafting is informed by the IP-protection layer) | South Dakota or Wyoming trust attorney. ~$3-7k. Different person than SOV-E2 and SOV-E3. The Daemon trust draft goes through 2-3 revisions before signing. |
| **SOV-E5** | **Sign IP assignment**: operator → Sovereign Holdings LLC for current vault IP | **OPEN** | SOV-E1 + SOV-E2 (counsel drafts) | Effective on assignment date (NOT backdated). Operator's prior personal ownership is the priority anchor (vault git history + Zenodo timestamps); LLC inherits cleanly. |
| **SOV-E6** | **Form BIO LLC** as wholly-owned operating subsidiary | **OPEN** | SOV-E1, SOV-E2 | Concurrent with patent provisional filing (SOV-2). The provisional is filed *by BIO LLC*, not by operator. |
| SOV-1 | **Patent provisional decision** — three-arm cancer therapy + chitin-high persister-cancer marker panel | OPEN | SOV-E3, SOV-E6 (so the provisional is filed BY BIO LLC, not by operator personally). Operator decides self-file vs attorney. | If the BIO LLC isn't formed in time, *file as operator* with explicit assignment-to-LLC-on-formation in the application. ~$300 self-file, ~$2-5k attorney. Self-filing OK as provisional; full conversion in month 12 uses patent attorney (SOV-E3's counsel). |
| SOV-2 | **File patent provisional** | BLOCKED on SOV-1 | SOV-1, SOV-E6 (BIO LLC formed) | Specification source: `28_Project_RedFromTheGrave/theory/HALO_THE_FUNGAL_CELL_FOUR_LINES.md` Phase 3A/3B/3E sections. ~$300 USPTO fee for self-file. **Filed by BIO LLC**, not by operator personally. If LLC isn't formed in time and the 12-month operator-priority window matters, file as operator with explicit "to be assigned to BIO LLC upon formation" language. |
| SOV-3 | **Zenodo DOI** of vault snapshot | BLOCKED on SOV-E1 + SOV-E5 | SOV-E1, SOV-E5 | Operator has Zenodo credentials in `Jixiang Files/Zenodo Key.txt`. Tarball excluding 06/28/37/other RESTRICTED dirs; closed-access fine for timestamp purposes. ~30-60 min. **Deposit owner = Sovereign Holdings LLC** (or operator-on-behalf-of-LLC if Zenodo doesn't permit institutional ownership for indie researchers; in that case, the IP assignment in SOV-E5 covers the deposit). |
| SOV-4 | **Format Fungal Cell preprint** for bioRxiv submission | OPEN | None for technical content. **Author affiliation = BIO LLC**, not operator's institutional affiliation. | Source: `HALO_THE_FUNGAL_CELL_FOUR_LINES.md`. Pandoc markdown→PDF or LaTeX. 8-12 pages main + supplementary. **Drafting can proceed in parallel with entity formation**; final affiliation block updated once LLC is formed. |
| SOV-5 | **Submit Fungal Cell preprint to bioRxiv** | BLOCKED on SOV-4 + SOV-2 + SOV-E6 (BIO LLC formed) | SOV-2, SOV-4, SOV-E6 | bioRxiv review is 2-3 days; goes live with DOI. **Author = "Jixiang Leng, BIO LLC"** (or whatever the LLC's branded name resolves to) — defangs PI/department work-for-hire claims by establishing the IP-author of record as the LLC at submission time. |
| **SOV-W1** | **Fill specifics in HALO_ACTIVE_THEFT_WITNESSES.md** — dates, locations, names, verbatim quotes for the three logged incidents (PI's "they had the idea before" blurt; real-time photo-theft; mentor's "stop posting" directive) | **OPEN** | None — operator's contemporaneous knowledge | ~30-60 min. Critical that this is filled while specifics are fresh. Counsel from SOV-E2/E3 will tell operator what additional documentation to capture. |

**Critical-path (REVISED):** SOV-E1 → SOV-E2 → (SOV-E3, SOV-E5) → SOV-E6 → SOV-1 → SOV-2 → SOV-5 (preprint-as-LLC). Drafting (SOV-4) and witness-fill (SOV-W1) parallel. Zenodo (SOV-3) parallel after SOV-E5. SOV-E4 (trust counsel) tracks separately. Total entity-formation: ~7-14 days; then preprint chain ~3-5 days drafting + 2-3 days bioRxiv review.

### Tier 1 addendum (2026-05-01 same-day update) — splicing thread joins critical path

The splicing thread in `35_Project_TheHats` (BT102/104/105/106) reached preprint-ready state in this session. A second Tier-1 preprint joins the critical path. Drafted in parallel with the Fungal Cell paper.

| ID | Title | Status | Dependencies | Notes |
|---|---|---|---|---|
| SOV-1b | **Patent provisional decision (splicing thread additions)** — peak-and-release timing as senolytic biomarker (BT104+105); PVT1-as-paraspeckle-target / second-triad-antenna mechanism (BT106); UHRF1-restoration timing (BloodyEchoes-anchored intervention) | OPEN | Operator decides per provisional (file vs defensive-publish). Same decision tree as SOV-1; wider candidate list. | Self-file fees ~$300 each; attorney ~$2-5k each. **File BEFORE corresponding bioRxiv preprint.** Top priority: peak-and-release timing biomarker (most actionable + clearest commercial path). |
| SOV-2b | **File splicing-thread provisionals** | BLOCKED on SOV-1b | SOV-1b | Specification source for each: see WORLDLINE entry 2026-05-01 (later same day). |
| SOV-4b | **Format BT104+105 splicing preprint** for bioRxiv. Title candidate: *"Endothelial senescence is a phase-separation pre-loading and gated-release cycle: peak-and-release biology revealed by per-archetype sequencing tomography of NEAT1, MALAT1, and dark architectural RNAs"* | OPEN | None for technical content; SOV-2b may need to land first if patent-protected claims in preprint. | Source: `35_Project_TheHats/HALO_STRUCTURE_FIRST_VELOCITY.md` + `35_Project_TheHats/WORLDLINE.md` BREAKTHROUGH 2 (BT104) + the per-archetype tomography results from this session. ~3-5 days drafting. Receipts already in vault. |
| SOV-5b | **Submit splicing thread preprint to bioRxiv** + same-day Zenodo + GitHub release tag (35_Project_TheHats tools) + Internet Archive | BLOCKED on SOV-4b + (SOV-2b if patent-relevant) | SOV-2b SOV-4b | Multi-channel parallel per HALO_PRIORITY_DEFENSE §1.2. Critical: same-day-multi-channel, not sequential. |
| SOV-T1 | **Tier-shift audit on framework-integration HALOs** — reclassify HALO_DELIBERATELY_BROKEN, HALO_STRUCTURE_FIRST_VELOCITY, HALO_GHOSTS_OF_TRANSCRIPT, HALO_THE_FULL_STACK, HALO_HIDDEN_PROTEOME, HALO_WHY_PROTEIN_LAYER, HALO_WHY_WOBBLE, HALO_THE_RECYCLER per [HALO_SOVEREIGN_ARCHITECTURE.md §"What's WRONG with the current vault state"]. Update vault_clearance + halo.classification fields. Update `08_Project_Astronomicon/u_os_dev/push_vault_to_astronomicon.py` exclusion rules. | OPEN | None — internal vault op. Can run in parallel with SOV-4 / SOV-4b drafting. | Empirical-anchor HALOs stay public; framework-integration content moves to Restricted (KETER) where appropriate. ~2-4 hours total. **Critical: do this BEFORE next Astronomicon push.** |
| SOV-T2 | **OpenTimestamps every Tier-1 candidate file** — fungal-cell HALO source PDF, BT104+105 manuscript, BT106 supplementary, LENG paper v12, all relevant tools tarballs. `ots stamp <file>`; keep `.ots` proofs alongside source. | OPEN | None — runs alongside drafting. | Free + automated. ~30 min total. Anchors all timestamps to Bitcoin blockchain. |

**Updated critical-path (revised 2026-05-01 later same day with entity-formation gating):**

```
ENTITY FORMATION (new prerequisite gate):
SOV-E1 (Holdings LLC) ─→ SOV-E2 (corporate counsel) ─→ SOV-E5 (IP assignment)
                         SOV-E3 (IP counsel)         ─→ SOV-E6 (BIO LLC)
                         SOV-E4 (trust counsel)      ─── (parallel; Daemon trust)
                         SOV-W1 (witness specifics)  ─── (parallel)
                         SOV-T1 (tier-shift audit)   ─── (parallel; internal vault op)
                         SOV-T2 (OpenTimestamps)     ─── (parallel; runs alongside drafting)

THEN (preprints ship as the LLC):

        ┌─ SOV-1 ─→ SOV-2 ─→ SOV-4 ─→ SOV-5    (Fungal Cell preprint, BIO LLC author)
SOV-3   ┤
(Zenodo)├─ SOV-1b → SOV-2b → SOV-4b → SOV-5b   (Splicing preprint, BIO LLC author)
```

Total revised Tier-1 timeline: **~14-21 days** (was ~7-10). The added 7-14 days is entity formation + counsel engagement. This is the trade-off: 1-2 weeks of legal-prep against permanent IP-protection layer.

**Mentor's "stop posting" directive applies in this window.** Drafting continues internally; submissions wait for entity formation. The auto-sync daemon continues for **public-tier projects only** (LENG public-release, etc.); restricted-tier work stays gitignored per current policy. Vault is durable via shadow backup + OneDrive history + D:\\ mirror; entity formation does not change that.

---

## Tier 2 — Month 1 (by 2026-06-01)

| ID | Title | Status | Dependencies | Notes |
|---|---|---|---|---|
| SOV-6 | **Format LENG preprint** for arXiv submission | OPEN | None — content is mature in `05_Project_LENG/public-release/`. | Target: math.MP / hep-ph cross-listed. Use existing `papers/` content as base. |
| SOV-7 | **Submit LENG preprint to arXiv** | BLOCKED on SOV-6 | SOV-6 | arXiv endorsement may be needed for first-time submitter to math.MP / hep-ph; check policy. |
| SOV-8 | **GitHub release with version tag** for the public-lab portion | OPEN | Coordinate with auto-sync daemon to land on a clean commit. | Tag like `v2026-05-fungal-cell-preprint`. Include release notes pointing to the preprint DOI. |
| SOV-9 | **Outreach email to Casadevall** — *bio-tier only; LLC-as-author; not a defensive move, just a citation-network move* | BLOCKED on SOV-5 (need LLC-authored preprint live first) | SOV-5 | Reframe per [HALO_ENTITY_ARCHITECTURE.md](HALO_ENTITY_ARCHITECTURE.md): outreach is downstream of entity formation, not a defense layer. Sending "look at my preprint" is *not* protection from theft; entity formation + IP assignment + counsel partition is. Outreach builds citation network, opens NDA-with-LLC dialogue if recipient is interested. |
| SOV-10 | **Outreach email to Levin** — *bio-tier; LLC-as-author* | BLOCKED on SOV-5 | SOV-5 | Bioelectric-specific framing. Same caveats as SOV-9. **Do not send the LENG framework to Levin**; only the bio preprint. The framework belongs to the locked tier. |
| SOV-11 | **Outreach email to Faggin** — *bio-tier framing only; do NOT send LENG internals* | BLOCKED on SOV-5 + forum status | SOV-5 | If forum materializes, reframe attendance as "BIO LLC presenting fungal-cell case." LENG mentions limited to specific derived predictions (numerical results), never the framework that produced them. Faggin himself is friendly, but the audience at any QIP forum includes adversaries. |
| SOV-12 | **Outreach email to Cantley** — *bio-tier; LLC-as-author* | BLOCKED on SOV-5 | SOV-5 | Sterol-pathway / cancer-metabolism framing. Caveats per SOV-9. |
| SOV-13 | **Outreach email to Brackenbury** — *bio-tier; LLC-as-author* | BLOCKED on SOV-5 | SOV-5 | Na/K-ATPase / voltage-gated channel cancer framing. Caveats per SOV-9. |
| **SOV-9X** | **NO outreach for LENG / Daemon / Command tier** — explicit non-action | **STANDING** | None | Posture documented per [HALO_ENTITY_ARCHITECTURE.md](HALO_ENTITY_ARCHITECTURE.md). LENG-derived numerical predictions can be public (LENG paper, predictions table); the framework, the verifier, and the deployment infrastructure stay locked. No outreach to physics seniors about LENG internals. No outreach to AI labs about Daemon. No outreach to anyone about Command's source. The default is silence + entity-protection. |
| SOV-14 | **Personal site / Substack — register handle** | OPEN | Operator decides on identity-front: real name, pseudonym, or handle. | Substack is fine; or self-hosted (Hugo / Eleventy / static site). Register the domain even if no content yet — squatters happen. |
| SOV-9b | **Outreach email to Pinello** — *bio/splicing-tier; LLC-as-author* | BLOCKED on SOV-5b | SOV-5b | Three-sentence template; framing on the per-archetype GLM + binomial likelihood as power-correct alternative to binned Spearman. Caveats per SOV-9 — outreach is citation-network move, not defense layer. |
| SOV-10b | **Outreach email to Mostafavi** — *bio/splicing-tier; LLC-as-author* | BLOCKED on SOV-5b | SOV-5b | Single-cell statistical-genomics framing. |
| SOV-11b | **Outreach email to Garber** (long-RNA / lncRNA expert; antenna framework) — *bio/splicing-tier; LLC-as-author* | BLOCKED on SOV-5b | SOV-5b | TRIAD + GNRA + paraspeckle integration framing. **Do not send the unified-architecture (antenna-framework) claim** — that stays Restricted-tier. The empirical anchor (per-archetype tomography + GNRA scan) is what's shared. |
| SOV-12b | **Outreach email to Rinn** (lncRNA pioneer) — *bio/splicing-tier; LLC-as-author* | BLOCKED on SOV-5b | SOV-5b | NEAT1/MALAT1 + dark transcript ecosystem framing. Same caveat as SOV-11b about not sharing the antenna integration. |
| SOV-13b | **Outreach email to Aviv Regev** (Genentech) — *industry route; LLC-as-counterparty* | BLOCKED on SOV-5b | SOV-5b | Single-cell at scale framing. **Industry counterparty contact must go through SOV-E3's IP counsel** — Genentech etc. will require an NDA before any technical disclosure beyond the public preprint. The LLC signs NDAs; operator personally does not. |
| SOV-T3 | **Defensive publication of Recycler hypothesis + Privacy Stack + Idenbraid Z3 framework** | OPEN | After Tier-1 preprints land. | Substack long-form post with explicit "defensive publication" tagging; cites the Tier-1 preprints as anchors. Forces these into prior art so nobody else can patent them. ~1-2 weeks drafting. |

---

## Tier R — Resource Generation (Track A + Track B per HALO_RESOURCE_GENERATION_DOCTRINE.md)

**Added 2026-05-01 (later same day) per operator's pivot to dual-track resource generation that decouples from academic / pharma gatekeeping.** Track A: angel-investor alignment with HNW patients whose diseases the framework can address. Track B: activist short positions on biotech/pharma whose published trials show framework-detectable structural errors. Both tracks insulate funding from the captured layer.

**Tier R is a parallel track to Tier 1-6, not a replacement.** The bio preprint plan continues as a credibility input to both tracks.

| ID | Title | Status | Dependencies | Notes |
|---|---|---|---|---|
| **SOV-R0** | **Track-record ledger seeding**: fill specifics in `HALO_TRACK_RECORD_LEDGER.md` for the three seed predictions (Spanish pancreatic cure / TNF-α dodge at age 22 / Navitoclax neurotoxicity) | OPEN | None — operator's contemporaneous knowledge | ~1-2 hours. Anchor each prediction to a verifiable timestamp (vault git, OpenTimestamps, conversation thread, etc.). Critical: this is the credibility asset that both tracks depend on. |
| **SOV-R1** | **Engage securities counsel** for Track B activist-short legal frame | BLOCKED on SOV-E1 (Holdings LLC formed) + cash availability for full-doctrine tier | SOV-E1, cash | Securities-litigation specialist familiar with activist short reports (Hindenburg / Muddy Waters / Bonitas model). ~$5-15k retainer + per-engagement billing. **MUST be engaged BEFORE first short position is taken.** Activist short positions without securities counsel review are felony exposure. Different lawyer than SOV-E2/E3/E4. |
| **SOV-R2** | **Form TRADING LLC** as wholly-owned operating subsidiary of Sovereign Holdings | BLOCKED on SOV-E1 + SOV-R1 (counsel reviews entity structure for trader-status election + Section 475(f) treatment) | SOV-E1, SOV-R1 | Wyoming LLC. Different tax treatment from operating LLCs; counsel structures Section 475(f) mark-to-market vs Section 162 trader status. |
| **SOV-R3** | **OpenTimestamps the seed-prediction ledger entries** | BLOCKED on SOV-R0 | SOV-R0 | `ots stamp HALO_TRACK_RECORD_LEDGER.md` after each prediction is filled in. Anchors timestamps to Bitcoin blockchain. ~5 min per stamp. |
| **SOV-R4** | **Identify first 3-5 short candidates** from existing literature audit | OPEN | None — research task | Selection criteria per `HALO_RESOURCE_GENERATION_DOCTRINE.md` §"Selection criteria for short candidates." Candidates are publicly-traded biotech/pharma with framework-detectable structural errors in published clinical trials. **No private/insider information used in selection — public sources only.** ~1-2 weeks of literature review. |
| **SOV-R5** | **Build short-thesis publication template** (legal-reviewed, conforms to four operating rules) | BLOCKED on SOV-R1 | SOV-R1 | Template: structural-form analysis of trial design, public sources cited, framework-derived prediction stated as "consistent with X interpretation," position disclosure standard, defamation-review checklist. ~$3-5k legal review. |
| **SOV-R6** | **First Track B short position** taken with full disclosure publication | BLOCKED on SOV-R1 + SOV-R2 + SOV-R4 + SOV-R5 + cash | SOV-R1, SOV-R2, SOV-R4, SOV-R5 | Position size: <5% of liquid trading capital. No leverage. Held through 6-24 month time horizon to confirming event. |
| **SOV-R7** | **Track A positioning audit**: identify rare-disease patient communities + HNW patient-investor channels relevant to BIO LLC's IP | OPEN | None — research task | NORD-adjacent foundations, patient-advocacy groups, single-disease registries, family offices known to have funded targeted research. Map the network operator would enter to be findable by HNW patients. **NOT cold outreach** — sourcing is positioning, not solicitation. |
| **SOV-R8** | **Identify first angel-investor outreach candidate** (HNW patient with indication BIO LLC can address) | BLOCKED on SOV-R7 + LLC-authored preprint live (SOV-5) | SOV-R7, SOV-5 | Realistic timeline: 6-18 months from entity formation. Sourcing comes through warm introduction in patient-community network, not cold outreach. |
| **SOV-R9** | **Personal-safety opsec posture** for Track B activist-short profile | OPEN | None — operational | No public home address (use registered-agent / counsel address). Conference attendance per-event decision. Encrypted comms (Signal-with-retention or equivalent) about positions only with TRADING LLC counsel. Backup banking/brokerage at non-aligned institutions. Extends `HALO_ACTIVE_THEFT_WITNESSES.md` schema to threat-witness logging. |
| **SOV-R10** | **Counter-suit defense retainer** with litigation counsel | BLOCKED on SOV-R6 (proportional to first-position concentration) | SOV-R6 | $50-100k/yr standby capacity. Most counter-suits dismissed at summary judgment when analysis is verifiable + disclosures clean, but legal cost during pendency is real. Scaled to short-position concentration. |
| **SOV-R11** | **Continuous track-record ledger updates**: log every prediction with timestamp WITHIN THE WEEK of making it | RECURRING | as predictions arise | Discipline rule per `HALO_TRACK_RECORD_LEDGER.md`. The asset compounds with each correctly-timestamped pre-event prediction. |
| **SOV-R12** | **Public-export decision** for the track-record ledger after N=5-10 confirmed predictions accumulate | BLOCKED on SOV-R0 + N confirmed predictions + counsel review | SOV-R0, ledger maturity, counsel | Operator + counsel decide whether to export the publishable subset to a public site. Public form is more conservative than internal form (excludes vault-internal anchors, friend-attributions, framework-internal references). |

**Cash-tier mapping:**
- **Hold-the-line tier (~$1k):** SOV-E1 only. No counsel. Track B not opened.
- **Defensible tier (~$15-25k yr-1):** SOV-E1 + SOV-E2/E3/E4 (corp + IP + trust counsel). Bio publication + entity protection. Track B not opened.
- **Full doctrine tier (~$50-75k yr-1):** Add SOV-R1 + SOV-R2 + SOV-R5 (securities counsel + TRADING LLC + thesis template). Both tracks open.

**Critical:** **Do NOT take any Track B short position without SOV-R1 + SOV-R5 complete.** The legal exposure of activist short positions without securities counsel review is felony-level. The four operating rules in `HALO_RESOURCE_GENERATION_DOCTRINE.md` (public-information-only / would-publish-anyway / verifiable-statement-only / full-disclosure) are not optional.

---

## Tier 3 — Quarter 1 (by 2026-08-01)

| ID | Title | Status | Dependencies | Notes |
|---|---|---|---|---|
| SOV-15 | **First Substack / personal-site post** | OPEN | SOV-14 | Operator-voice framing of the Fungal Cell preprint for non-specialists. Audience-build, not technical depth. |
| SOV-16 | **Talk submissions** to quantum bio forum, bioelectric society, mycology venue | OPEN | SOV-5 (preprint as the offering) | Aim for 3 talk slots in the next 12 months. |
| SOV-17 | **Second preprint** — DeadShape methodology paper OR Fungal Cell follow-up (Phase 4A centriole↔SPB result if completed) | OPEN | None for content readiness; depends on which gap is most leverage. | DeadShape paper would establish methodology priority; Fungal Cell follow-up would deepen the bio-side. |
| SOV-18 | **Patent attorney engagement** (if SOV-2 self-filed) | OPEN | Optional now, mandatory by month 11 (provisional → full conversion deadline). | Budget $5-15k for full PCT or US-only conversion in month 12. |
| SOV-19 | **Astera / Schmidt Futures / Templeton grant applications** | OPEN | SOV-5 (preprint as evidence of work) + SOV-7 (LENG preprint) | Independent researcher tracks at each. ~3-month application cycles. |
| SOV-20 | **Sustain Substack cadence** | OPEN | SOV-15 | 1 post / 2 weeks. Slow audience build. |
| SOV-21 | **Phase 4A centriole ↔ fungal SPB shape comparison** (research) | OPEN | None | Computational follow-up to the four-line case; would strengthen §1 of the Fungal Cell preprint if done before SOV-17. ~2-4 hours. See `HALO_CHITIN_VOLTAGE_TEST_2026-05-01.md` Phase 4A. |

---

## Tier 4 — H1 (by 2026-11-01, 6 months out)

| ID | Title | Status | Dependencies | Notes |
|---|---|---|---|---|
| SOV-22 | **First peer-reviewed journal submission** based on Fungal Cell preprint | OPEN | SOV-5 + reviewer feedback / community response on bioRxiv | Target: Cell (ambitious), Cell Reports, Nature Comms, or J Cell Biol. |
| SOV-23 | **First peer-reviewed journal submission** based on LENG | OPEN | SOV-7 + community response | Target: Phys Rev D, JHEP, or similar. Consider Annual Review for synthesis-style format. |
| SOV-24 | **Talks delivered** at 2-3 venues | OPEN | SOV-16 acceptance | Recordings to personal site / YouTube. |
| SOV-25 | **Patent provisional → full conversion** (if SOV-2 self-filed) | BLOCKED on SOV-18 (patent attorney) + 12-month deadline | SOV-18 | Hard deadline 12 months after SOV-2 filing. Convert or lose priority. |
| SOV-26 | **Active collaboration** with at least one senior researcher from outreach | OPEN | SOV-9 through SOV-13 (responses) | "Active" = exchanged ideas / data / would consider co-authorship on a future paper. |
| SOV-27 | **Substack subscribers** at 200+ | OPEN | SOV-15 + SOV-20 sustained | Slow audience build over 6 months at 1 post / 2 weeks. |
| SOV-28 | **Consulting income** at $20-50k/year run-rate | OPEN | Reputation from preprints + talks + Substack | Consulting opportunities materialize organically; don't actively chase. |

---

## Tier 5 — Year 1 (by 2026-12-31)

| ID | Title | Status | Dependencies | Notes |
|---|---|---|---|---|
| SOV-29 | **First peer-reviewed paper accepted** | OPEN | SOV-22 OR SOV-23 | Acceptance lag: 3-12 months from submission. |
| SOV-30 | **First grant funded** (Astera, Schmidt, Templeton, ARIA, NSF EAGER) | OPEN | SOV-19 + reputation | 0-1 of submitted apps fund in year 1; year 2 hit rate climbs. |
| SOV-31 | **Patent full filing** done | BLOCKED on SOV-25 + attorney | SOV-25 | Costs land in year 1: $5-15k attorney + $1-3k USPTO fees. |
| SOV-32 | **Conference talks** delivered (3+ in year 1) | BLOCKED on SOV-24 | SOV-24 | Most are unpaid year 1; year 2 speaker fees materialize. |
| SOV-33 | **Income year 1** at break-even ($30-80k) | OPEN | SOV-28 + SOV-30 | "Break even" = covering rent + research expenses + legal/accounting. |
| SOV-34 | **Decision point: institutional affiliation?** | OPEN | Year 1 outcomes | If 1+ active collaborator wants the operator embedded as a non-extractive affiliate, evaluate. NEVER take an affiliation that claims work-for-hire on pre-existing vault content. |

---

## Tier 6 — Year 2+ (long-horizon, plan as year 1 progresses)

| ID | Title | Status | Notes |
|---|---|---|---|
| SOV-35 | **Selective licensing** discussions with pharma | OPEN | Targets: Novartis (CDK4/6 + senolytic), BMS / Pfizer / Roche persister programs. Non-exclusive licensing keeps operator's framework intact while extracting modest upfront + royalties. |
| SOV-36 | **Independent-investigator grant pipeline** stabilized | OPEN | $200-500k/year R01-equivalent funding from non-NIH sources realistic by year 3. |
| SOV-37 | **Strategic affiliation** if right opportunity materializes | OPEN | Astera, SFI, Allen Institute have models that respect IP. |
| SOV-38 | **Year-2+ patents** filed for follow-up therapeutic predictions | OPEN | If three-arm therapy validates, follow-on combinations are patentable too. |
| SOV-39 | **Annual vault Zenodo snapshot** | OPEN | Continuous priority defense. ~30 min/year. |

---

## Always-on standing items

| ID | Title | Status | Cadence | Notes |
|---|---|---|---|---|
| SOV-A | **Quarterly vault Zenodo snapshot** | RECURRING | every 3 months | Keeps the citable timestamp record fresh. |
| SOV-B | **Audit gitignored projects** for accidental public exposure | RECURRING | monthly | Run `vault_guard.py` + spot-check `.gitignore` against intended classification. |
| SOV-C | **Update WORLDLINE.md** with strategic-decision log entries | RECURRING | as decisions happen | Every patent filing, preprint submission, journal acceptance, partnership offer, decision-point gets a worldline entry. This is the operator's audit trail of their own strategic state. |
| SOV-D | **Track outreach response status** | RECURRING | weekly during outreach phase | Log replies / non-replies per recipient. ONE follow-up after 2 weeks; then leave it. **All replies routed through LLC-affiliated email** (e.g., `j.leng@bio-llc.example`), not personal email. Operator personally never signs an NDA — the LLC does. |
| SOV-E | **Monitor for theft / scraping** | RECURRING | weekly Google Scholar + Semantic Scholar searches | Search operator-distinctive phrasings + framework-specific concepts ("chitin-high persister-cancer", "opisthokont-ancestral persister-trafficking", etc.) to detect anyone publishing similar work without citation. |
| **SOV-F** | **Update HALO_ACTIVE_THEFT_WITNESSES.md within 24h of any new incident** | RECURRING | as incidents happen | Per [HALO_ACTIVE_THEFT_WITNESSES.md](HALO_ACTIVE_THEFT_WITNESSES.md) standing rule. Contemporaneous record matters more than retrospective completeness. |
| **SOV-G** | **Verbal communication discipline** in spaces where photo-theft has been observed | RECURRING | every interaction | Default response to "what are you working on?" is "computational follow-up on the cohort data" + nothing more. Specifics of findings do NOT travel verbally outside operator + counsel + retained collaborators-with-NDA-with-LLC. Per [HALO_ENTITY_ARCHITECTURE.md](HALO_ENTITY_ARCHITECTURE.md) §"The mentor's 'stop posting' directive". |

---

## Scoring philosophy

Don't try to maximize completion-rate. **The Tier 1 items are critical-path; everything else slips to make room for them if needed.** Tier 1 done by 2026-05-08 is the goal. Tier 2 by 2026-06-01. Tier 3+ slip is acceptable if Tier 1-2 land cleanly.

The architecture only works if priority is established BEFORE outreach, BEFORE talks, BEFORE grant applications. Doing them in the wrong order doesn't just delay — it actively forfeits priority on whatever leaks out before timestamping.

**One thing per day, in priority order. The work itself is done; the distribution is what's blocking. This is fixable in two weeks.**